Ambrx today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1/2 dose escalation and dose expansion clinical trial in metastatic castration resistant prostate cancer (mCRPC). For details: https://bit.ly/410TRaP
Helping Pharma and Biotech CEOs Drive Exponential Growth and Results || Champion for the Impossible
11moCongrats on this exciting clinical update on ARX517! Keep up the amazing work!